Late line treatment in hormone receptor positive, her 2 neu positive metastatic breast cancer with fulvestrant, abemaciclib, and trastuzumab, including prolonged CNS control.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Author: Albert Guy Wendt
Institutions: St. Joseph's Hospital and Medical Center, Dignity Health
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162690952
Cites:
Cited by:
Related to: